Efficacy and safety of thalidomide in patients with hepatocellular carcinoma

Table 5 Thalidomide-related adverse events in patients with HCC

	Grade of severity (n)					Total
Adverse event	G1	G2	G3	G4	G5	n (%)
Constipation	2	22	0	0	0	24 (57)
Skin rash	6	8	3	0	0	17 (41)
Low leg edema	1	10	0	0	0	11 (26)
Dizziness	3	5	1	0	0	9 (21)
Lethargy	3	2	2	0	0	7 (17)
Nausea/vomiting	1	5	0	0	0	6 (14)
Neurosensory	3	0	0	0	0	3 (7)
Dyspnea	0	2	0	0	0	2 (5)
Leukopenia	1	0	0	0	0	1 (2)
Thrombocytopenic purpura	0	1	0	0	0	1 (2)
Insomnia	0	1	0	0	0	1 (2)
Alopecia	1	0	0	0	0	1 (2)

¹mild adverse event;

²Moderate adverse event;

³Severe adverse event;

⁴Life-threatening or disabling adverse event;

⁵Death related to adverse event.